Dose doubling, relative potency, and dose equivalence of potassium-sparing diuretics affecting blood pressure and serum potassium: Systematic review and meta-analyses

Journal of Hypertension

Volumn 34, Issue 1, 2016, Pages 11-19

  Roush, George C ^a   Ernst, Michael E ^b   Kostis, John B ^c   Yeasmin, Shamima ^b   Sica, Domenic A ^d  

^a ST VINCENT S MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

amiloride; diuretics; eplerenone; spironolactone; triamterene

Indexed keywords

AMILORIDE; EPLERENONE; POTASSIUM; POTASSIUM SPARING DIURETIC AGENT; SPIRONOLACTONE; TRIAMTERENE; ANTIHYPERTENSIVE AGENT; THIAZIDE DIURETIC AGENT;

DRUG EFFICACY; DRUG POTENCY; HUMAN; HYPERKALEMIA; HYPERTENSION; META ANALYSIS; PHARMACEUTICAL EQUIVALENCE; PHARMACOLOGICAL PARAMETERS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECONDARY ANALYSIS; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; ANALOGS AND DERIVATIVES; BLOOD; BLOOD PRESSURE; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; THERAPEUTIC EQUIVALENCE;

AMILORIDE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERKALEMIA; POTASSIUM; SODIUM CHLORIDE SYMPORTER INHIBITORS; SPIRONOLACTONE; THERAPEUTIC EQUIVALENCY; TRIAMTERENE;

EID: 84951567446     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000762     Document Type: Review

References (34)

1. James PA, Oparil S, Carter BL, Cushman WC, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311:507-520.
2. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich) 2014; 16:14-26.
3. Sica DA. Chapter 130. Thiazide and loop diuretics. In: Izzo Jr J, Black HR, Sica DA, editors. Hypertension primer. Dallas, TX: American Heart Association; 2008. p. 441.
4. Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens 2004; 22:2217-2226.
5. Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens 2008; 2:462-468.
6. Engbaek M, Hjerrild M, Hallas J, Jacobsen IA. The effect of low-dose spironolactone on resistant hypertension. J Am Soc Hypertens 2010; 4:290-294.
7. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al., American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008; 117:e510-e526.
8. Law M, Wald MJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003; 326:1427-1431.
9. Peterzan MA, Hardy R, Chaturvedi N, Hughes AD. Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate. Hypertension 2012; 59:1104-1109.
10. Wright JM, Lee CH, Chambers GK. Systematic review of antihypertensive therapies: does the evidence assist in choosing a first-line drug? CMAJ 1999; 161:25-32.
11. Baguet JP, Robitail S, Boyer L, Debensason D, Auquier P. A metaanalytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Am J Cardiovasc Drugs 2005; 5:131-140.
12. Ernst ME, Carter BL, Zheng S, Grimm RH. Meta-analysis of doseresponse characteristics of hydrochlorothiazide and chlorthalidone: effects on systolic blood pressure and potassium. Am J Hypertens 2010; 23:440-446.
13. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Int Med 2009; 151:264-269; W264.
14. Batterink J, Stabler SN, Tejani AM, Fowkes CT. Spironolactone for hypertension. Cochrane Database Syst Rev 2010; (8):CD008169.
15. Heran BS, Chen JM, Wang JJ, Wright JM. Blood pressure lowering efficacy of potassium-sparing diuretics (that block the epithelial sodium channel) for primary hypertension. Cochrane Database Syst Rev 2012; 11:CD008167.
16. Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. The Cochrane Collaboration and John Wiley & Sons Ltd; 2008; pages 191, 192, 510, 511.
17. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-634.
18. Borenstein M, Hedges LV, Higgins JPT, Rothstein HR. Introduction to meta-analysis. The Atrium, Southern Gate, Chichester, West Sussex, UK:: John Wiley and Sons Ltd; 2009; pages 187-204.
19. Sumner DJ, Meredith PA, Elliott HL. Initial blood pressure as a predictor of the response to antihypertensive therapy. Br J Clin Pharmacol 1988; 26:715-720.
20. Maxwell MH, Brachfeld J, Itskovitz H, Lunn JA, Moser M, Zawada ET. Blood pressure lowering and potassium conservation by triamterenehydrochlorothiazide and amiloride-hydrochlorothiazide in hypertension. Clin Pharmacol Ther 1985; 37:61-65.
21. Holland OB, Nixon JV, Kuhnert A. Diuretic-induced ventricular ectopic activity. Am J Med 1981; 70:762-768.
22. Holland OB, Kuhnert L, Pollard J, Padia M, Anderson RJ, Blomqvist G. Ventricular ectopic activity with diuretic therapy. Am J Hypertens 1988; 1 (4 Pt 1):380-385.
23. Siscovick DS, Raghunathan TE, Psaty BM, Koepsell TD, Wicklund KG, Lin X, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994; 330:1852-1857.
24. Wing LM, Reid CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, et al., Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348:583-592.
25. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al., ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high risk patients. N Engl J Med 2008; 359:2417-2428.
26. Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension 2012; 59:1110-1117.
27. Amery A, Birkenhäger W, Brixko P, Bulpitt C, Clement D, Deruyttere M, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; 1:1349-1354.
28. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356:366-372.
29. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304:405-412.
30. Roush GC, Ernst ME, Kostis JB, Kaur R, Sica DA. Not just chlorthalidone: evidence-based, single tablet, diuretic alternatives to hydrochlorothiazide for hypertension. Curr Hypertens Rep 2015; 17:31; 1-11.
31. Hebert PR, Coffey CS, Byrne DW, Scott TA, Fagard RH, Rottman JN, et al. Treatment of elderly hypertensive patients with epithelial sodium channel inhibitors combined with a thiazide diuretic reduces coronary mortality and sudden cardiac death. J Am Soc Hypertens 2008; 2:355-365.
32. Bapoje SR, Bahia A, Hokanson JE, Peterson PN, Heidenreich PA, Lindenfeld J, et al. Effects of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with left ventricular systolic dysfunction: a meta-analysis of randomized controlled trials. Circ Heart Fail 2013; 6:166-173.
33. Sica DA, Flack JM. Treatment considerations with aldosterone receptor antagonists. Curr Concepts Pharmacother Hypertens 2011; 13:65-69.
34. Oates JA, Brown NJ. Chapter 34. Antihypertensive agents and the drug therapy of hypertension. In: Hardman JG, Limbird LE, editors. Goodman & Gilman's the pharmacological basis of therapeutics, 10th edition. McGraw-Hill; 2001. p. 874.